TR200200732T2 - Antidiyabetik ve antiobesite maddeleri olarak faydalı oksa-ve tiyazol türevleri - Google Patents

Antidiyabetik ve antiobesite maddeleri olarak faydalı oksa-ve tiyazol türevleri

Info

Publication number
TR200200732T2
TR200200732T2 TR2002/00732T TR200200732T TR200200732T2 TR 200200732 T2 TR200200732 T2 TR 200200732T2 TR 2002/00732 T TR2002/00732 T TR 2002/00732T TR 200200732 T TR200200732 T TR 200200732T TR 200200732 T2 TR200200732 T2 TR 200200732T2
Authority
TR
Turkey
Prior art keywords
antidiabetic
oxa
derivatives useful
antiobesity agents
thiazole derivatives
Prior art date
Application number
TR2002/00732T
Other languages
English (en)
Inventor
T.W.Cheng Peter
Devasthale Pratik
T. Jeon Yoon
Chen Sean
Zhang Hao
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of TR200200732T2 publication Critical patent/TR200200732T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Q'nun C veya N; A'nin O veya S; Z'nin O veya bir bag; X'in CH veya N ve R1,R2,R2a,R2b,R2c,R3,Y,x,m, ve n'nin burada tanimlandigi gibi oldugu (I) yapisina sahip bilesikler saglanmistir;bu bilesikler, antidiyabetik, hipolipidemik ve antiobesite maddeleri olarak faydalidir.
TR2002/00732T 1999-09-22 2000-09-19 Antidiyabetik ve antiobesite maddeleri olarak faydalı oksa-ve tiyazol türevleri TR200200732T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15540099P 1999-09-22 1999-09-22

Publications (1)

Publication Number Publication Date
TR200200732T2 true TR200200732T2 (tr) 2002-10-21

Family

ID=22555274

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00732T TR200200732T2 (tr) 1999-09-22 2000-09-19 Antidiyabetik ve antiobesite maddeleri olarak faydalı oksa-ve tiyazol türevleri

Country Status (28)

Country Link
US (1) US7579479B2 (tr)
EP (1) EP1218361B1 (tr)
JP (2) JP4332315B2 (tr)
KR (1) KR100682419B1 (tr)
CN (1) CN1289490C (tr)
AR (1) AR025756A1 (tr)
AT (1) ATE420080T1 (tr)
AU (1) AU782031B2 (tr)
BR (1) BR0014189A (tr)
CA (1) CA2388452C (tr)
CO (1) CO5200832A1 (tr)
DE (1) DE60041343D1 (tr)
EG (1) EG24169A (tr)
ES (1) ES2319097T3 (tr)
HK (1) HK1049337B (tr)
HU (1) HUP0204416A3 (tr)
IL (2) IL147939A0 (tr)
MX (1) MXPA02001847A (tr)
MY (1) MY138525A (tr)
NO (1) NO322500B1 (tr)
NZ (1) NZ516820A (tr)
PE (1) PE20010643A1 (tr)
PL (1) PL364986A1 (tr)
RU (2) RU2279427C2 (tr)
TR (1) TR200200732T2 (tr)
TW (4) TWI302149B (tr)
WO (1) WO2001021602A1 (tr)
ZA (1) ZA200200937B (tr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
TWI302149B (en) * 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
ATE341343T1 (de) 2000-12-26 2006-10-15 Sankyo Co Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
EP1394154A4 (en) * 2001-03-23 2005-05-18 Takeda Pharmaceutical FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
AU2002323776B2 (en) * 2001-08-10 2008-07-31 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor Delta
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
TW200300681A (en) 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
KR20040068240A (ko) * 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AU2003259131A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AR041481A1 (es) 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10311984A1 (de) * 2003-03-12 2004-09-23 Freie Universität Berlin Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten
EA008798B1 (ru) * 2003-06-13 2007-08-31 Лабораториос С.А.Л.В.А.Т., С.А. НОВЫЕ БЕНЗАМИДЫ В КАЧЕСТВЕ PPARγ МОДУЛЯТОРОВ
WO2005000309A2 (en) * 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US20070275956A1 (en) * 2003-10-14 2007-11-29 Lohray Braj B Novel Heterocyclic Compounds
CN1870997B (zh) 2003-10-24 2011-05-04 参天制药株式会社 角膜结膜病变的治疗剂
US7348329B2 (en) 2003-10-29 2008-03-25 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
JP2007230868A (ja) * 2004-03-30 2007-09-13 Dai Ichi Seiyaku Co Ltd 二環性化合物及びそれを用いた医薬
JPWO2005095364A1 (ja) * 2004-03-30 2008-02-21 第一三共株式会社 フェノキシ酢酸誘導体及びそれを用いた医薬
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
CN1968932A (zh) 2004-06-18 2007-05-23 惠氏公司 制备6－烷基－5－芳基磺酰基－二氢菲啶的方法
KR100739367B1 (ko) * 2004-07-14 2007-07-16 크리스탈지노믹스(주) 설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2006117743A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
EP1943215A2 (en) 2005-10-31 2008-07-16 Brystol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2897536A1 (fr) * 2006-02-17 2007-08-24 Galderma Res & Dev Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7795291B2 (en) * 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
KR100958831B1 (ko) * 2006-09-19 2010-05-24 주식회사유한양행 헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
ES2465216T3 (es) 2007-06-04 2014-06-05 Ben Gurion University Of The Negev Research And Development Authority Compuestos de triarilo y composiciones que comprenden los mismos
CN101711238A (zh) 2007-06-11 2010-05-19 百时美施贵宝公司 1,3-二羟基取代的苯基酰胺葡糖激酶激活剂
KR20110022620A (ko) 2008-05-30 2011-03-07 다케다 야쿠힌 고교 가부시키가이샤 복소환 화합물
WO2010004319A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt
KR101036406B1 (ko) * 2008-10-24 2011-05-24 박란 축구공
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
JP5784623B2 (ja) 2009-11-13 2015-09-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 速放性錠剤製剤
EP3315124B1 (en) 2009-11-13 2021-01-06 Astrazeneca AB Bilayer tablet formulations
CN102711738A (zh) 2009-11-13 2012-10-03 百时美施贵宝公司 质量得以减小的二甲双胍制剂
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN103370064A (zh) 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
CA2826391C (en) 2011-02-01 2017-01-24 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
JP6007417B2 (ja) * 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
EP2574607A1 (en) 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
PL3489226T3 (pl) 2012-11-20 2021-08-02 Lexicon Pharmaceuticals, Inc. Inhibitory kotransportera glukozowo-sodowego 1
CN109867630A (zh) 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
CN103694195B (zh) * 2013-09-18 2016-04-06 华东师范大学 芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
AU2015360364B2 (en) 2014-12-10 2020-04-30 Receptos Llc GLP-1 receptor modulators
US10829437B2 (en) * 2015-04-02 2020-11-10 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
US10968192B2 (en) 2018-09-26 2021-04-06 Lexicon Pharmaceuticals, Inc. Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
CN114981251B (zh) * 2020-01-21 2023-11-21 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途
JP7407651B2 (ja) * 2020-04-20 2024-01-04 東ソー・ファインケム株式会社 ３－アセトキシスチレンの製造方法
EP4615433A1 (en) 2022-11-08 2025-09-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036079A (en) 1989-12-07 1991-07-30 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5037819A (en) 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5250677A (en) 1990-06-04 1993-10-05 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5110812A (en) 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
US5175283A (en) 1990-06-04 1992-12-29 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
TW222626B (tr) * 1991-07-22 1994-04-21 Pfizer
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
EP1011651B1 (en) 1996-02-02 2005-04-27 Merck & Co., Inc. Method of treating diabetes and related disease states
DE69720429T9 (de) 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
ATE262334T1 (de) 1996-02-02 2004-04-15 Merck & Co Inc Antidiabetisches mittel
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (ja) * 1996-04-03 2001-10-02 日本たばこ産業株式会社 プロピオン酸誘導体及びその用途
ZA973850B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
JP2000515501A (ja) 1996-07-01 2000-11-21 イーライ・リリー・アンド・カンパニー 低血糖化および低脂血化用化合物群
JP2000515133A (ja) 1996-07-01 2000-11-14 イーライ・リリー・アンド・カンパニー 血糖降下性および脂質低下性の化合物
WO1998027974A1 (en) 1996-12-23 1998-07-02 Merck & Co., Inc. Antidiabetic agents
WO1999007357A1 (en) 1997-08-08 1999-02-18 Ono Pharmaceutical Co., Ltd. η-TYPE REGULATORS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
WO1999011255A1 (en) 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
AU9002798A (en) 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
BR9814087A (pt) 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
EP1177176B1 (en) 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Tri-aryl acid derivatives as ppar receptor ligands
TWI302149B (en) * 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method

Also Published As

Publication number Publication date
RU2279427C2 (ru) 2006-07-10
NZ516820A (en) 2004-11-26
IL147939A0 (en) 2002-08-14
KR20020047179A (ko) 2002-06-21
US7579479B2 (en) 2009-08-25
JP2009102360A (ja) 2009-05-14
JP4332315B2 (ja) 2009-09-16
BR0014189A (pt) 2002-08-20
RU2002108928A (ru) 2004-01-10
TW200528436A (en) 2005-09-01
JP2003509503A (ja) 2003-03-11
PL364986A1 (en) 2004-12-27
CN1374955A (zh) 2002-10-16
CO5200832A1 (es) 2002-09-27
TWI260321B (en) 2006-08-21
CA2388452A1 (en) 2001-03-29
CA2388452C (en) 2007-04-03
AU7593500A (en) 2001-04-24
MXPA02001847A (es) 2002-10-23
IL147939A (en) 2008-03-20
ZA200200937B (en) 2003-07-30
HK1049337A1 (en) 2003-05-09
RU2005117879A (ru) 2006-11-20
AU782031B2 (en) 2005-06-30
EP1218361A1 (en) 2002-07-03
TW200514783A (en) 2005-05-01
HUP0204416A2 (hu) 2003-04-28
KR100682419B1 (ko) 2007-02-28
WO2001021602A1 (en) 2001-03-29
NO20021408D0 (no) 2002-03-21
MY138525A (en) 2009-06-30
EG24169A (en) 2008-09-10
TW200538446A (en) 2005-12-01
NO322500B1 (no) 2006-10-16
HK1049337B (zh) 2007-07-27
DE60041343D1 (de) 2009-02-26
PE20010643A1 (es) 2001-08-18
ATE420080T1 (de) 2009-01-15
EP1218361B1 (en) 2009-01-07
AR025756A1 (es) 2002-12-11
ES2319097T3 (es) 2009-05-04
TWI302149B (en) 2008-10-21
NO20021408L (no) 2002-05-14
US20070015797A1 (en) 2007-01-18
RU2327692C2 (ru) 2008-06-27
HUP0204416A3 (en) 2006-01-30
CN1289490C (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
TR200200732T2 (tr) Antidiyabetik ve antiobesite maddeleri olarak faydalı oksa-ve tiyazol türevleri
NL350077I2 (nl) Cyprosulfamide
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
CU22869A3 (es) 1-aril-pirazoles plaguicidas
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
AR006390A1 (es) Derivados de lactama
BR0209783A (pt) Derivados de azul de metileno biologicamente ativos
GT199600026A (es) Isotiazolonas
DE60029857D1 (de) Lichtempfindliche Zusammensetzung und 1,3-dihydro-1-oxo-2H-Indenderivat
WO2000047580A3 (en) Phenyl urea and phenyl thiourea derivatives
SE0004245D0 (sv) Novel compounds and their use
DK1042319T3 (da) Dihydrobenzofuraner
ATE172975T1 (de) Benzimidezolderivate mit antidiabetischer und anti-plättchenklumpungswirkung
TR200400650T3 (tr) Antidiyabetik maddeler ve antiobezite maddeleri olarak yararlı ikame edilmiş azol asit türevleri ve yöntem
DE60017374D1 (de) Antibakterielle mittel
TR200103685T2 (tr) Optik olarak aktif pirrolopiridazin türevleri
ATE239768T1 (de) Neue triphendisoxazinpigmente
DE60022876D1 (de) Triphendioxazin-verbindungen
TR200103042T2 (tr) N”rotrofin g‡lendiricileri
ES2061182T3 (es) 2-fluoroneplanocina a y su fabricacion.
BR0110328A (pt) Compostos heterocìclicos com atividade antiinflamatória
UY26350A1 (es) Derivados de acidos substituidos empleados como agentes antidiabeticos y antiobesidad y metodo
BR0003216A (pt) Pó de vidro e uso do mesmo
MX9603273A (es) Tetrahidropirimidinas artropodicidas.
DE50002692D1 (de) Kalender